BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mizuno T, Ebata T, Yokoyama Y, Igami T, Sugawara G, Yamaguchi J, Nagino M. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis. Surg Today 2017;47:182-92. [DOI: 10.1007/s00595-016-1354-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Yamada T, Nakanishi Y, Hayashi H, Tanishima S, Mori R, Fujii K, Okamura K, Tsuchikawa T, Nakamura T, Noji T, Asano T, Matsui A, Tanaka K, Watanabe Y, Kurashima Y, Ebihara Y, Murakami S, Shichinohe T, Mitsuhashi T, Hirano S. Targeted amplicon sequencing for primary tumors and matched lymph node metastases in patients with extrahepatic cholangiocarcinoma. HPB (Oxford) 2021:S1365-182X(21)01703-2. [PMID: 34903468 DOI: 10.1016/j.hpb.2021.11.008] [Reference Citation Analysis]
2 Liang L, Li C, Wang MD, Xing H, Diao YK, Jia HD, Lau WY, Pawlik TM, Zhang CW, Shen F, Huang DS, Yang T. The value of lymphadenectomy in surgical resection of perihilar cholangiocarcinoma: a systematic review and meta-analysis. Int J Clin Oncol 2021;26:1575-86. [PMID: 34160742 DOI: 10.1007/s10147-021-01967-z] [Reference Citation Analysis]
3 Asukai K, Kawamoto K, Eguchi H, Konno M, Asai A, Iwagami Y, Yamada D, Asaoka T, Noda T, Wada H, Gotoh K, Nishida N, Satoh T, Doki Y, Mori M, Ishii H. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma. Ann Surg Oncol 2017;24:2344-52. [PMID: 28560603 DOI: 10.1245/s10434-017-5871-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
4 Ebata T, Mizuno T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Watanabe N, Nagino M. Predictive performance of Blumgart T staging for perihilar cholangiocarcinoma in a Japanese center. J Hepatobiliary Pancreat Sci 2020;27:132-40. [PMID: 31654600 DOI: 10.1002/jhbp.694] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Ohiwa T, Ebata T, Mizuno T, Yokoyama Y, Yamaguchi J, Onoe S, Watanabe N, Nagino M. Occult synchronous liver metastasis from perihilar cholangiocarcinoma. Surgery 2019;166:290-6. [PMID: 31235246 DOI: 10.1016/j.surg.2019.04.029] [Reference Citation Analysis]
6 Chen X, Meng F, Xiong H, Zou Y. Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis. Front Oncol 2021;11:600027. [PMID: 33777744 DOI: 10.3389/fonc.2021.600027] [Reference Citation Analysis]
7 Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37:1015-1027. [PMID: 30856044 DOI: 10.1200/jco.18.02178] [Cited by in Crossref: 113] [Cited by in F6Publishing: 47] [Article Influence: 37.7] [Reference Citation Analysis]
8 Zhao J, Zhang W, Zhang J, Chen YT, Ma WJ, Liu SY, Li FY, Song B. Independent Risk Factors of Early Recurrence After Curative Resection for Perihilar Cholangiocarcinoma: Adjuvant Chemotherapy May Be Beneficial in Early Recurrence Subgroup. Cancer Manag Res 2020;12:13111-23. [PMID: 33376403 DOI: 10.2147/CMAR.S289094] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ebata T, Mizuno T, Yokoyama Y, Igami T, Sugawara G, Nagino M. Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. Br J Surg. 2018;105:829-838. [PMID: 28488733 DOI: 10.1002/bjs.10556] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 9.4] [Reference Citation Analysis]
10 Mori S, Aoki T, Park K, Shiraki T, Sakuraoka Y, Iso Y, Kato M, Kubota K. Impact of preoperative percutaneous transhepatic biliary drainage on post‐operative survival in patients with distal cholangiocarcinoma. ANZ Journal of Surgery 2019;89. [DOI: 10.1111/ans.15329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
11 Ghidini M, Tomasello G, Botticelli A, Barni S, Zabbialini G, Seghezzi S, Passalacqua R, Braconi C, Petrelli F. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB (Oxford). 2017;19:741-748. [PMID: 28684194 DOI: 10.1016/j.hpb.2017.05.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
12 Seita K, Ebata T, Mizuno T, Maeda A, Yamaguchi R, Kurumiya Y, Sakamoto E, Hiramatsu K, Ando M, Nagino M. Phase 2 Trial of Adjuvant Chemotherapy With S - 1 for Node-Positive Biliary Tract Cancer (N-SOG 09). Ann Surg Oncol 2020;27:2348-56. [PMID: 32180066 DOI: 10.1245/s10434-020-08355-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
13 Toyoda Y, Ebata T, Mizuno T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Watanabe N, Nagino M. Cholangiographic Tumor Classification for Simple Patient Selection Prior to Hepatopancreatoduodenectomy for Cholangiocarcinoma. Ann Surg Oncol. 2019;26:2971-2979. [PMID: 31102092 DOI: 10.1245/s10434-019-07457-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Kamarajah SK, Al-Rawashdeh W, Parente A, Atherton P, Salti GI, Dahdaleh FS, Manas D, Hilal MA, White SA. Adjuvant chemotherapy for perihilar cholangiocarcinoma: A population-based comparative cohort study. Eur J Surg Oncol 2021:S0748-7983(21)00949-5. [PMID: 34916085 DOI: 10.1016/j.ejso.2021.12.002] [Reference Citation Analysis]
15 Shinke G, Yamada D, Eguchi H, Iwagami Y, Akita H, Asaoka T, Noda T, Gotoh K, Kobayashi S, Takeda Y, Tanemura M, Doki Y, Mori M. The postoperative peak number of leukocytes after hepatectomy is a significant prognostic factor for cholangiocarcinoma. Mol Clin Oncol 2019;10:531-40. [PMID: 31007913 DOI: 10.3892/mco.2019.1827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Wang ML, Ke ZY, Yin S, Liu CH, Huang Q. The effect of adjuvant chemotherapy in resectable cholangiocarcinoma: A meta-analysis and systematic review. Hepatobiliary Pancreat Dis Int 2019;18:110-6. [PMID: 30470543 DOI: 10.1016/j.hbpd.2018.11.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
17 Luvira V, Satitkarnmanee E, Pugkhem A, Kietpeerakool C, Lumbiganon P, Pattanittum P. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma. Cochrane Database Syst Rev 2021;9:CD012814. [PMID: 34515993 DOI: 10.1002/14651858.CD012814.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Donati M, Stang A, Stavrou GA, Basile F, Oldhafer KJ. Extending resectability of hilar cholangiocarcinomas: how can it be assessed and improved? Future Oncol 2019;15:193-205. [PMID: 30378439 DOI: 10.2217/fon-2018-0413] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ma WJ, Jin YW, Wu ZR, Yang Q, Wang JK, Liu F, Shi YJ, Li QS, Cheng NS. Meta-analysis of randomized clinical trials of adjuvant chemotherapy for resected biliary tract cancers. HPB (Oxford) 2020;22:939-49. [PMID: 32349925 DOI: 10.1016/j.hpb.2020.02.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
20 Im JH, Choi GH, Lee WJ, Han DH, Park SW, Bang S, Choi HJ, Seong J. Adjuvant radiotherapy and chemotherapy offer a recurrence and survival benefit in patients with resected perihilar cholangiocarcinoma. J Cancer Res Clin Oncol 2021;147:2435-45. [PMID: 33471185 DOI: 10.1007/s00432-021-03524-7] [Reference Citation Analysis]
21 Okumura Y, Noda T, Eguchi H, Sakamoto T, Iwagami Y, Yamada D, Asaoka T, Wada H, Kawamoto K, Gotoh K, Kobayashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer. Ann Surg Oncol 2018;25:3728-37. [PMID: 30105440 DOI: 10.1245/s10434-018-6670-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
22 Lu J, Li B, Li FY, Ye H, Xiong XZ, Cheng NS. Prognostic significance of mucinous component in hilar cholangiocarcinoma after curative-intent resection. J Surg Oncol 2019;120:1341-9. [PMID: 31612493 DOI: 10.1002/jso.25722] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
23 Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, Kaneoka Y, Yamamoto M, Ambo Y, Shimizu Y, Ozawa F, Fukutomi A, Ando M, Nimura Y, Nagino M; Bile Duct Cancer Adjuvant Trial (BCAT) Study Group. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192-202. [PMID: 29405274 DOI: 10.1002/bjs.10776] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 28.3] [Reference Citation Analysis]
24 Siebenhüner AR, Seifert H, Bachmann H, Seifert B, Winder T, Feilchenfeldt J, Breitenstein S, Clavien PA, Stupp R, Knuth A, Pestalozzi B, Samaras P. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. BMC Cancer 2018;18:72. [PMID: 29325521 DOI: 10.1186/s12885-017-3967-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
25 Nassour I, Mokdad AA, Porembka MR, Choti MA, Polanco PM, Mansour JC, Minter RM, Wang SC, Yopp AC. Adjuvant Therapy Is Associated With Improved Survival in Resected Perihilar Cholangiocarcinoma: A Propensity Matched Study. Ann Surg Oncol. 2018;25:1193-1201. [PMID: 29488187 DOI: 10.1245/s10434-018-6388-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
26 Lu J, Li B, Li FY, Ye H, Xiong XZ, Cheng NS. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma involving the hepatic hilus versus hilar cholangiocarcinoma after curative-intent resection: Should they be recognized as perihilar cholangiocarcinoma or differentiated? Eur J Surg Oncol 2019;45:2173-9. [PMID: 31208772 DOI: 10.1016/j.ejso.2019.06.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Jansen H, Pape UF, Utku N. A review of systemic therapy in biliary tract carcinoma. J Gastrointest Oncol 2020;11:770-89. [PMID: 32953160 DOI: 10.21037/jgo-20-203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]